1. Home
  2. SVV vs TRVI Comparison

SVV vs TRVI Comparison

Compare SVV & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Savers Value Village Inc.

SVV

Savers Value Village Inc.

HOLD

Current Price

$7.23

Market Cap

1.4B

ML Signal

HOLD

Logo Trevi Therapeutics Inc.

TRVI

Trevi Therapeutics Inc.

HOLD

Current Price

$15.36

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SVV
TRVI
Founded
1954
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Other Specialty Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.4B
IPO Year
2021
2019

Fundamental Metrics

Financial Performance
Metric
SVV
TRVI
Price
$7.23
$15.36
Analyst Decision
Buy
Strong Buy
Analyst Count
6
11
Target Price
$13.67
$21.55
AVG Volume (30 Days)
981.6K
1.8M
Earning Date
05-06-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
31.91
EPS
N/A
N/A
Revenue
$1,678,954,000.00
N/A
Revenue This Year
$6.91
N/A
Revenue Next Year
$7.80
N/A
P/E Ratio
N/A
N/A
Revenue Growth
9.19
N/A
52 Week Low
$6.91
$5.38
52 Week High
$13.89
$16.12

Technical Indicators

Market Signals
Indicator
SVV
TRVI
Relative Strength Index (RSI) 32.98 65.92
Support Level $6.91 $10.07
Resistance Level $8.95 $16.12
Average True Range (ATR) 0.40 0.77
MACD -0.14 0.00
Stochastic Oscillator 13.19 83.40

Price Performance

Historical Comparison
SVV
TRVI

About SVV Savers Value Village Inc.

Savers Value Village Inc is a for-profit thrift operator in the United States and Canada. It purchases second-hand textiles (i.e., clothing, bedding, and bath items), shoes, accessories, housewares, books, and other goods from its non-profit partners (NPPs), either directly from them or via on-site donations (OSDs) at Community Donation Centers at its stores. The company then processes, selects, prices, and sells these items in its stores.

About TRVI Trevi Therapeutics Inc.

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.

Share on Social Networks: